Aviva’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Aviva’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-27,877	Closed	-$3.67M	–	994
2020 Q4	$3.67M	Sell	27,877 -22,599	-45%	-$2M	0.02%	559
2020 Q3	$2.55M	Sell	50,476 -423	-0.8%	-$19K	0.02%	591
2020 Q2	$2.43M	Sell	50,899 -22,207	-30%	-$1.03M	0.02%	579
2020 Q1	$3.58M	Buy	+73,106	New	+$3.72M	0.03%	590

Aviva's EIDX Position: Q1 2021 in Review

Aviva sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 27,877 shares — an estimated $3.67M sold.

Aviva first reported a position in EIDX in Q1 2020 and held it in 4 quarters. The position peaked at $3.67M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Aviva reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Aviva sold 27,877 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $3.67M.
Aviva first reported a position in Eidos Therapeutics, Inc. Common Stock in Q1 2020 and held it in 4 quarters.
Aviva's Eidos Therapeutics, Inc. Common Stock position peaked at $3.67M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Aviva's 13F filing for Q1 2021, filed 13 May 2021.